The Netherlands is also suspending the use of Ast …

Holland joins the list of countries that stopping use of the AstraZeneca vaccine against the coronavirus preventively after clots have been detected in people who had been inoculated.

This Sunday, the Netherlands announced that they would suspend vaccination with the drug produced by the Anglo-Swedish laboratory until March 28, after “possible side effects” were reported in Denmark and Norway.

The Danish Directorate General for Health (SST) reported in a press release last week that the suspension came “after reports of serious cases of training of blood clots in people vaccinated with the AstraZeneca covid-19 vaccine “and one of these people died. The state body also pointed out that “At the moment, we cannot conclude that there is a relationship between the vaccine and blood clots”.

The Norwegian government, for its part, said it had detected four serious cases of blood clots in vaccinated adults and on Saturday reported skin hemorrhages in young people who received the vaccine.

Other countries that have temporarily suspended the use of the AstraZeneca vaccine are Ireland, Iceland, Bulgaria, Thailand and the Republic of Congo.

In the Italian region of Piedmont (north-west), which On Sunday, the AstraZeneca vaccine administration briefly suspended After the death of a teacher vaccinated the day before, it was decided to resume the application, although as a precaution he withdrew a batch of vaccine from the Anglo-Swedish laboratory.

The President of the Italian Medicines Agency (AIFA), Giorgio Palu, assured that AstraZeneca vaccine poses “no risk” and believes “the benefits far outweigh the risks”, for which he asked to overcome “emotionality” and rely on “scientific data”.

during, from AstraZeneca, they issued a statement in which they state that the “careful examination of all available safety data on the more than 17 million people in the European Union and the United Kingdom” which they have received from your vaccine “has not provided any evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia in a given age group, sex, lot or country. “

AstraZeneca argued that the 15 cases of deep vein thrombosis and the 22 pulmonary embolism recorded among those who received the vaccine represent a percentage “much lower than what should occur naturally in a general population“.

Andrew Pollard, director of the Oxford Vaccine Group, said: “There is very reassuring evidence that there is no increase in the thrombus phenomenon here in the UK, where the majority of doses in Europe have so far been administered. “

The World Health Organization (WHO) said on Friday that “there is no reason not to use” this vaccine.

However, the European Medicines Agency (EMA) considers a cause and effect relationship to be “probable” in at least some cases of “41 reports of possible anaphylaxis observed among 5 million people vaccinated in the UK”.

For AstraZeneca, these issues are in addition to the new revision of the drop in supply to the European Union in June and that the laboratory was forced to report alleged export problems.